


FDA Oncology Center of Excellence and the BAA program

Julie Schneider, Ph.D. Associate Director for Research Strategy and Partnerships, OCE




The mission of the Oncology Center of Excellence is to achieve **patient-centered** regulatory decision-making through innovation and collaboration



FDA

Introduction to the Oncology Center of Excellence



FDA



Regulatory Issues: FDA

An Analysis of Recent FDA Oncology Scientific Publications

JULIE A. SCHNEIDER , ANDREW C. MIKLOS, JAMES ONKEN, VITAO GONG, ANNA MARIA CALCAGNO, GIDEON M. BLUMENTHAL, RICHARD ARAGON, RICHARD PAZDUR^a ^aOncology Center of Excellence and ^bOffice of Hematology and Oncology Products, U.S. Food and Drug Administration, Silver Spring, Mary T.D.A.; ^cOffice of Program Planning, Analysis, and Evaluation, National Institute of General Medical Science, National Institute DA alo, NECO, LOGRY, UP, apgell Secale Cial Col, ICI Chie, CarylaO, US, Nigh-Impact Disclosures of potential conflicts of interest may be found at the end of this article. Publications at and bo have about bitwees times the number of citations as an average NIH-funded paper

ABSTRACT

In addition to its primary regulatory role, the Office of Hematology and Oncology Products at the U.S. Food and Drug Administration (FDA) is engaged in many forms of scientific authorship. During the period of 2010 to 2018, FDA oncology staff contributed to 356 publications in the scientific literature. Here, we collaborated with analysts in the Office of Program Planning, Analysis, and Evaluation at the National Institute of General Medical Sciences, National Institutes of Health (NIH), to present a series of analyses aimed at quantifying the characteristics and potential impact of these contributions, as well as characterizing the

areas of work addressed. We found that FDA oncology papers are enriched for high-impact publications and have about two times the number of citations as an average NIHfunded paper. Further impact of the publications was measured based on the presence or 65 publications that were cited by guidelines and 12 publications cited by publicly listed clinical trials. The results seen here are promising in determining the impact of FDA oncology publication work but prompt further investigation into longer-term impacts, such as the influence of this work on other regulatory activities at FDA. **The Oncologist** 2020;25:266–270 D)



Support FDA scientific staff to plan and conduct high quality applied research that addresses challenges identified during regulatory review of oncology therapeutics



Cell /Gene and personalized neo-antigen-based therapies for cancer

Health equity and special populations in oncology clinical trials

Immuno-oncology

Oncology trial designs, end points and statistical methodologies

Pediatric oncology

Precision oncology

Oncology patient-focused drug development

Oncology safety

Rare cancers


Real world data utilization (cross cutting)

For more information please visit: OCE Scientific Collaborative Website



Cell/gene and personalized neo-antigen-based therapies for cancer

Applied research related to clinical development, safety evaluation, manufacturing, and quality control of innovative approaches such as gene editing-based technology (e.g., CRISPR-Cas9), cell therapy (e.g., TIL, TCR-T, CAR-T) for solid and hematologic malignancies, and neo-antigen-based cancer therapy.





Health equity and special populations in oncology drug development

Applied research to understand the factors that affect the safety and treatment response in demographic subgroups that have been historically underrepresented in oncology trials (e.g., racial/ethnic minorities, sexual and gender minorities, older adults).





Immuno-oncology

Applied research to analyze clinical and scientific issues unique to regulatory submissions of immuno-oncology products such as understanding unique side effects and atypical responses (e.g., delayed progression, pseudo-progression) to immune checkpoint inhibitors.





Oncology patient-focused drug development


Applied research to promote scientifically rigorous use of clinical outcome measures to quantify symptoms and function in oncology. Develop and create standard clinical endpoints, analytic and visualization methods, and use of digital health technology to further characterize a products safety and efficacy.





Oncology trial designs, endpoints and statistical methodologies

Innovative approaches for statistical analyses of oncology clinical trials. Identify, develop or refine endpoints (e.g., real world endpoints defined and extracted using EHR data or novel early endpoints) that could be used in clinical studies to inform regulatory submissions.





Oncology therapeutic safety

New approaches to allow for consistent and rigorous analysis of safety signals throughout the lifecycle of oncology therapeutics and to improve understanding of toxicity from oncology therapeutics in the patient population. Explore use of real-world data to inform post-marketing safety.





Pediatric oncology

Applied research to accelerate the development of oncology therapeutics for children, for example through developing new preclinical models, novel trial designs, and use of real world data.









Precision oncology

Applied research to develop and deploy biomarkers (e.g., molecular, imaging) to accelerate and improve regulatory review of oncology therapeutics.





OCE scientific interest areas



Rare cancers

Applied research to develop new approaches to support drug development in rare cancers such as drug repurposing, telemedicine and innovative trial designs and analysis of real world data.





Oncology real world data utilization (cross-cutting)

Approaches to evaluate, integrate, and facilitate the use of oncology real world data (e.g., electronic health records, administrative health claims, drug or disease registries, patient reported or generated health data) to generate high quality real world evidence





For more information about active OCE-funded BAA projects visit

OCE-Funded Active Extramural Research Projects



Questions?

Please contact: FDAOncology@fda.hhs.gov